Clinical Study of Chemotherapy Combined With Chinese Medicine on Survival Affect of Elderly Patients With Lung Cancer

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to observe the efficacy of chemotherapy combined with Traditional Chinese Medicine for elderly patients with advanced non-small-cell lung cancer, also to evaluate the adverse reaction and the reliability.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine
• Collaborators: Fudan University; Shanghai Chest Hospital
• Treatments: Docetaxel; Gemcitabine; Vinorelbine

Criteria

Inclusion Criteria:

1. Pathologically or cytologically confirmed of stage IIIb-IV NSCLC ;

2. Ages Eligible for Study: ≥65 years old;

3. Physical status score (ECOG PS) ≤ 2 scores;

4. Estimated life expectancy of at least 12 weeks;

5. Participants have no major organ dysfunction and chemotherapy contraindications:

hemoglobin ≥9g/dL, absolute neutrophil count (ANC) ≥1.5*109/L, platelets ≥100 *109/L,bilirubin≤1.5ULN,alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 upper limited number(ULN) (AP, AST, ALT ≤5ULN is acceptable if liver has tumor involvement).INR≤1.5, APTT in the normal range(1.2DLN-1.2ULN),creatinine≤1.5ULN;

6. Informed consent from the patient.

Exclusion Criteria:

1. Patient with other malignant tumor except NSCLC 5 years previous to study entry.

2. Patients who have received single-agent chemotherapy treatment；

3. Estimated life expectancy less than 12 weeks;

4. Serious problem of heart, liver or kidney with severe dysfunction;

5. Pregnant or child breast feeding women;

6. Mental or cognitive disorders;

7. Participating in other drug trials;

8. Who are allergic to the study drug.